Cargando…

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

BACKGROUND: In a previous pooled analysis of 12 double-blind clinical studies that included data on 6,139 patients with type 2 diabetes, treatment with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was shown to be generally well tolerated compared with treatment with control agents. As cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams-Herman, Debora, Engel, Samuel S, Round, Elizabeth, Johnson, Jeremy, Golm, Gregory T, Guo, Hua, Musser, Bret J, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161395/ https://www.ncbi.nlm.nih.gov/pubmed/20412573 http://dx.doi.org/10.1186/1472-6823-10-7

Ejemplares similares

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
por: Engel, Samuel S., et al.
Publicado: (2013)

Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
por: Engel, Samuel S., et al.
Publicado: (2013)

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
por: Williams-Herman, Debora, et al.
Publicado: (2008)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
por: Engel, S S, et al.
Publicado: (2010)

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
por: Arjona Ferreira, Juan Camilo, et al.
Publicado: (2013)

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine
por: Mathieu, Chantal, et al.
Publicado: (2015)

Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
por: Ommen, Elizabeth S., et al.
Publicado: (2015)

Erratum to: Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
por: Ommen, Elizabeth S., et al.
Publicado: (2015)

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2016)

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
por: Miller, Sam, et al.
Publicado: (2018)

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study
por: Roussel, Ronan, et al.
Publicado: (2018)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
por: Tajima, Naoko, et al.
Publicado: (2019)

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study
por: Dagogo‐Jack, Samuel, et al.
Publicado: (2017)

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
por: Raji, Annaswamy, et al.
Publicado: (2020)

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
por: Pratley, Richard E., et al.
Publicado: (2018)

Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance
por: Kaku, K., et al.
Publicado: (2015)

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial
por: Al Sifri, S, et al.
Publicado: (2011)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin
por: Seino, Yutaka, et al.
Publicado: (2021)

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials
por: Raji, Annaswamy, et al.
Publicado: (2018)

A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes
por: Gantz, Ira, et al.
Publicado: (2017)

Sitagliptin-induced hemolysis
por: Bekur, Ragini, et al.
Publicado: (2010)

Sitagliptin-Associated Angioedema
por: Gosmanov, Aidar R., et al.
Publicado: (2012)

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study
por: Scott, Russell, et al.
Publicado: (2018)

Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance
por: Osei, Elizabeth, et al.
Publicado: (2021)

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin
por: Steinberg, Helmut, et al.
Publicado: (2013)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
por: Cho, Yong Kyun
Publicado: (2018)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Rhinorrhea, cough and fatigue in patients taking sitagliptin
por: Baraniuk, James N, et al.
Publicado: (2010)

Fixed drug eruption to sitagliptin
por: Gupta, Mrinal, et al.
Publicado: (2015)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
por: Sayari, Saba, et al.
Publicado: (2018)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
por: Goldenberg, Ronald, et al.
Publicado: (2017)

Sitagliptin: Is It Effective in Routine Clinical Practice?
por: Mohan Dallumal, Rita, et al.
Publicado: (2015)

Unresponsive Intractable Chronic Headache With Sitagliptin
por: Zaghloul, Ahmed, et al.
Publicado: (2018)

Is sitagliptin effective for the treatment of COVID-19?
por: Memiş, Hasan, et al.
Publicado: (2022)

Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study
por: Frias, Juan P., et al.
Publicado: (2019)

Health Tract, No. 246: Cellars
Publicado: (1866)

Cannot write session to /tmp/vufind_sessions/sess_2pg42bfbf2ff9cb32l5ei6nku7